Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Artemisinin and artemisinin derivatives as anti-fibrotic therapeutics

Acta Pharmaceutica Sinica B(2020)10.1016/j.apsb.2020.09.001Source: DataRank Database

Artemisinin and artemisinin derivatives as anti-fibrotic therapeutics is a research paper published in Acta Pharmaceutica Sinica B (2020). On theSindex it has a DataRank of 0. It has been cited 132 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access132 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 6.40)OA: goldTopics (64)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Pamela J. Weathers ORCID,Tanja Dominko ORCID,David Dolivo ORCID

Live enrichment

PubMed:33643815 PMC:PMC7893118 OpenAlex:https://openalex.org/W3083859449

Guangzhou Medical University

Grant: NIH-2R15AT008277-02

NCCIH NIH HHS

Grant: R15 AT008277

National Institutes of Health

Grant: 2R15AT008277-02

Study how the liver alters bioavailability of artemisinin when delivered from the dried leaves of the plant Artemisia annua vs as pure drug.

National Center for Complementary and Integrative Health

National Institutes of Health

FWCI

6.40

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.apsb.2020.09.001

publisherhttps://doi.org/10.1016/j.apsb.2020.09.001

publisherhttps://api.elsevier.com/content/article/PII:S2211383520307012?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211383520307012?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33643815

Fields of Study

Multiple Myeloma Research and TreatmentsDrug-Induced Hepatotoxicity and ProtectionResearch on Leishmaniasis Studies0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

ArtemisininPharmacologyFibrosisArtemisia annuaMedicineIn vivoArtesunateImmunologyBiologyMalariaPlasmodium falciparumPathologyBiotechnologyArtemisiaFibroblastSCARmyofibroblastTGF-βStz, StreptozotocinBsa, Bovine Serum AlbuminRos, Reactive Oxygen SpeciesDha, DihydroartemisininMapk, Mitogen-activated Protein KinaseMmp, Matrix MetalloproteinaseEcm, Extracellular MatrixHsc, Hepatic Stellate CellAmpk, Amp-activated Protein KinaseLdh, Lactate DehydrogenaseAlp, Alkaline PhosphataseCcl4, Carbon TetrachloridePcna, Proliferating Cell Nuclear AntigenAlt, Alanine AminotransferaseBun, Blood Urea NitrogenMi, Myocardial InfarctionNicd, Notch Intracellular DomainEmt, Epithelial-to-mesenchymal TransitionHuvec, Human Umbilical Vein Endothelial CellLap, Latency-associated PeptideTimp, Tissue Inhibitor Of MetalloproteinaseBdl, Bile Duct LigationUuo, Unilateral Ureteral ObstructionAsp, Aspartate AminotransferaseBad, Bcl-2-associated Agonist Of Cell DeathCol I, Type I CollagenDla, Dried Leaf ArtemisiaFls, Fibroblast-like SynoviocytePhn, Passive Heymann NephritisTgf, Β-transforming Growth Factor-βΑ-sma, Smooth Muscle Α-actinHa, Hyaluronic AcidMtor, Mechanistic Target Of RapamycinCtgf, Connective Tissue Growth FactorI.p., IntraperitonealScr, Serum CreatinineNag, N-acetyl-β-d-glucosaminidaseTherapeutics. PharmacologyRM1-950Review

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being